Business Wire

Softr Unveils an AI-Native Platform, Ushering in a New Era of Business Software Creation Without Code

31.3.2026 13:00:00 CEST | Business Wire | Press release

Share

New AI-platform enables non-tech teams to build fully functional, secure applications for real business operations, not just prototypes

Softr today evolved into an AI-native platform, marking the end of the AI prototype era and the beginning of production-ready business software that non-technical teams can build, own, and maintain with AI — without writing a single line of code. With the introduction of its new AI Co-Builder, Softr enables teams to replace spreadsheets and manual workflows with secure, fully-functional business applications, including internal tools, customer portals, partner platforms, and operational systems, simply by describing what they need.

This milestone marks a major evolution for Softr, a leading player in the no-code software category over the past five years. Since launching in 2020, the company has grown to support more than 1 million builders and 7,000 organizations, including Netflix, Google, Stripe, UPS, and Clay.

Softr’s new platform was built to bridge the gap between AI-generated prototypes and software that can actually run business operations. Many AI app builders promise instant software from a single prompt, but stop at surface-level outputs, requiring users to manage code, fix errors, and rebuild workflows from scratch. Business software, on the other hand, runs on real data, connects to internal systems, and supports users with defined roles and permissions in real time — it has to work 100 percent of the time. When AI builders fall short or stop at the prototype, only a developer can fix it — resulting in months of work and hundreds of thousands of dollars to get software that should have been ready on day one. Softr closes that gap.

Softr’s new AI-native platform enables organizations to move from fragmented tools to fully operational software systems built in minutes — designed to run securely on live data, integrate with internal infrastructure, and provide structured access and governance from day one.

“For the first time, AI made the idea that ‘I can build something myself’ mainstream for millions of people — but most AI app-builders stop at the shiny demo stage,” said Mariam Hakobyan, Co-Founder and CEO of Softr. “We built Softr to solve the hard parts of software building. Every business app, from an internal HR portal to a client-facing tool, runs on real data, users, permissions, and security. It has to work every single time. Our goal has always been to give non-technical teams the ability to build the custom solutions they need without relying on developers. This evolution turns that vision into reality: software that helps people build and run the mission-critical software that powers their business operations.”

With the addition of Softr’s AI Co-Builder, users can describe the software they need in plain language, and the platform generates a fully integrated system — including the database, user interface, permissions, and business logic — connected and ready for real-world users immediately. Core foundations such as authentication, user roles, permissions, and hosting are built in from the start, eliminating the need for teams to configure or manage them separately.

Softr’s platform is built for business software that teams and customers can depend on every day. Each application is:

  • Secure and fully functional from day one, with built-in authentication and permissions
  • Powered by a visual, user-friendly database, giving users full control over their data
  • Built on custom workflows and integrations, ensuring systems work seamlessly across tools
  • Easy to maintain and evolve, without requiring code or repeated prompting

Teams use Softr to power critical workflows such as client portals, CRMs, company intranets, and operational systems across a wide range of industries. The company is now combining that profitable foundation with AI to accelerate its mission: to empower billions of business users to create production-ready software they can rely on from day one.

“The future of software isn’t written — it’s created,” Hakobyan added. “The next generation of software will be built by everyone — not because we simplified code, but because we simplified creation — and made building hard things easy.”

About Softr

Softr is the AI-native platform for building the software your business runs on—portals, internal tools, and operational systems—without code or developers. Describe what you need, and AI creates the database, app, and business logic—already connected, secure, and ready for real users. Over 1M+ organizations, from startups to enterprises like Netflix, Google, Stripe, UPS, and Clay, run their business operations on Softr-built apps. Visit softr.io to learn more.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260331754358/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye